Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAL-506440 (H10N8 mRNA) in healthy adults
NCT03076385Phase 1Completed
- Sponsor
- Moderna Inc
- Start
- Dec 2015
- Primary completion
- Oct 2018
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Influenza A (H10N8) comparing VAL-506440 with Placebo (2 arms). Primary endpoint: Types, frequency, and severity of serious adverse events (SAE), adverse events of special interest (AESI), and adverse events considered related to study drug at 13 months. Started Dec 2015; status: completed.
02
Drugs
mRNA-1440
03
Conditions
Influenza A (H10N8)
Beyond the preview
Go deeper on NCT03076385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03076385.